Yescarta Suspension
Product Images NDC 71287-119

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Yescarta (NDC 71287-119). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Kite Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Yescarta 06)

A Kaplan-Meier survival curve chart showing the probability of event-free survival (%) over time since randomization in months, comparing YESCARTA (axicabtagene ciloleucel) treatment arm and Standard Therapy. The chart includes a table of subjects at risk for each group over time intervals up to 36 months.*

FDA Label Image

Figure 2 (Yescarta 07)

A Kaplan-Meier survival probability plot comparing YESCARTA cellular therapy versus standard therapy over time since randomization in months. The y-axis shows survival probability percentage, and the x-axis shows time in months up to 60. Data points for subjects at risk are provided below the graph for each treatment arm.*

FDA Label Image

Principal Display Panel (Patient ID Label)

Label for YESCARTA (axicabtagene ciloleucel) cellular therapy suspension for intravenous use, showing patient verification details including lot number, patient IDs, expiration and birth dates, with branding and barcodes. Manufactured by Kite Pharma, Inc.*

FDA Label Image

Secondary Cassette Label (Yescarta 02)

Label for YESCARTA axicabtagene ciloleucel suspension for intravenous use by Kite Pharma, Inc. The label includes a prominent red STOP sign instructing to confirm patient ID prior to infusion. It displays patient verification information such as lot number, Kite patient ID, expiration date, patient name, date of birth, hospital patient ID, and a barcode for DIN.*

FDA Label Image

Principal Display Panel (Lot Label)

Label for YESCARTA (axicabtagene ciloleucel) cellular therapy suspension by Kite Pharma, Inc. Includes product name and logo, cell order barcode and number, lot barcode and number, and manufacturing site information in Santa Monica, CA. Contact phone number is masked.*

FDA Label Image

Principal Display Panel (68 mL Bag Cassette Label)

Label for YESCARTA (axicabtagene ciloleucel) intravenous suspension, a cellular therapy product by Kite Pharma, Inc. It indicates use as one sterile bag for infusion containing approximately 68 mL suspension. The label includes storage instructions in vapor phase liquid nitrogen at or below -150°C and warnings against using a leukodepleting filter or irradiating the product. It also mentions the product is preservative free and manufactured with gentamicin.*

FDA Label Image

Principal Display Panel (68 mL Bag Label)

YESCARTA (axicabtagene ciloleucel) label for cellular therapy suspension, intravenous use, strength 2000000 1/68 mL. The label includes dosage instructions for one sterile bag for infusion and storage conditions in vapor phase liquid nitrogen at or below -150°C. Manufacturer is Kite Pharma, Inc., Santa Monica, CA, with a phone number and U.S. license information shown.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.